注射用核糖核酸Ⅱ联合培美曲塞+铂类化疗在非小细胞肺癌中的应用效果  

Effectiveness of Ribonucleic AcidⅡfor Injection in Combination with Pemetrexed+Platinum-based Chemotherapy in Non-small Cell Carcinoma

作　　者：李子立[1] 弓婷婷[2] 马丽霞[1] 张婷婷[1] 张洋[1] 崔洪霞[1] LI Zili;GONG Tingting;MA Lixia;ZHANG Tingting;ZHANG Yang;CUI Hongxia(Jilin Cancer Hospital,Changchun 130012,China;不详)

机构地区：[1]吉林省肿瘤医院,吉林长春130012 [2]吉林大学第二医院

出　　处：《中国医学创新》2023年第28期46-50,共5页Medical Innovation of China

摘　　要：目的:探讨注射用核糖核酸Ⅱ联合培美曲塞+铂类化疗在非小细胞肺癌(NSCLC)中的应用效果。方法:选取2019年6月—2021年6月于吉林省肿瘤医院诊治的80例NSCLC患者,使用随机数字表法将其分为观察组40例及对照组40例。对照组接受培美曲塞^(+)铂类化疗,观察组在对照组基础上加用注射用核糖核酸Ⅱ。对比两组的临床疗效、免疫功能指标、生活质量评分及肿瘤标志物指标。结果:观察组的客观反应率(ORR)、疾病控制率(DCR)均高于对照组,差异均有统计学意义(P<0.05)。治疗前,两组的CD3^(+)、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+)、CD4^(+)/CD25^(+)水平相较差异均无统计学意义(P>0.05);治疗6周后,两组的CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)、CD4^(+)/CD25^(+)均降低,但观察组均高于对照组,对照组CD8^(+)升高,但观察组低于对照组,差异均有统计学意义(P<0.05)。治疗前,两组各项癌症患者生活质量核心问卷评分相较差异均无统计学意义(P>0.05);治疗6周后,两组各项评分均升高,观察组均高于对照组,差异均有统计学意义(P<0.05)。治疗前,两组的血清癌胚抗原(CEA)、糖类抗原125(CA125)、细胞角蛋白19(CK-19)水平相较差异均无统计学意义(P>0.05);治疗6周后,两组的三项指标均降低,观察组均低于对照组,差异均有统计学意义(P<0.05)。结论:注射用核糖核酸Ⅱ联合培美曲塞+铂类化疗治疗NSCLC效果显著,减少化疗对免疫功能的损害,调节肿瘤标志物水平,提高生活质量。Objective:To investigate the effect of Injectable Ribonucleic AcidⅡcombined with Pemetrexed^(+)Platinum-based chemotherapy in non-small cell carcinoma(NSCLC).Method:Eighty patients with NSCLC treated in Jilin Cancer Hospital from June 2019 to June 2021 were selected and divided into 40 cases in the observation group and 40 cases in the control group using the random number table method.The control group received Pemetrexed+Platinum-based chemotherapy,while the observation group added Ribonucleic AcidⅡfor Injection on the basis of the control group. The clinical efficacy, immune function index, quality of life score and tumour marker indexes of the two groups were compared. Result: The objective response rate (ORR) and disease control rate (DCR) of the observation group were higher than those of the control group (P<0.05). Before treatment, the levels of CD3^(+), CD4^(+), CD8^(+), CD4^(+)/CD8^(+) and CD4^(+)/CD25^(+) were not significantly different between the two groups (P>0.05);after 6 weeks of treatment, the levels of CD3^(+), CD4^(+), CD4^(+)/CD8^(+) and CD4^(+)/CD25^(+) decreased in the both group, but those in the observation group were higher than those in the control group, and CD8^(+) increased in control group, but that of the observation group was lower than that of the control group (P<0.05). Before treatment, there were no significant differences between the two groups in the scores of the quality of life core questionnaire for cancer patients (P>0.05);after 6 weeks of treatment, the scores of both groups increased, those in the observation group were higher than those in the control group (P<0.05). Before treatment, there were no significant differences in serum carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125) and cytokeratin 19 (CK-19) levels between the two groups (P>0.05);after 6 weeks of treatment, all three indicators decreased in both groups, those in the observation group were lower than those in the control group (P<0.05). Conclusion: The combination of Ribonucleic Acid �

关 键 词：非小细胞肺癌 培美曲塞 铂类 注射用核糖核酸Ⅱ 免疫功能 肿瘤标志物 

分 类 号：R734.2[医药卫生—肿瘤]